Foundational Treatments for Tomorrow

SOMA Nutraceuticals, Inc., a Texas wholly owned subsidiary of AngioSoma, Inc., provides nutraceutical products, both patented and proprietary formulated, that integrate fully into AngioSoma, Inc.’s mission statement of having a complete solution for the treatment of cardiovascular disease – prior to the need for treatment to prevent the need for treatment (SOMA Nutraceuticals, Inc.), at treatment to bring patients up to a foundational level (Liprostin™ and the OmniCath I & II), and once patients have gotten to a foundational level to keep them at that level (the Transdermal PGE-1 Patch)

Our Nutraceutical Products

These products have previously generated over ten million dollars ($10,000,000) in sales, through various sales outlets including GNC, while these products were owned and marketed by Endovasc, Inc. in 2005 and 2006:

  • A patented (U.S. Patent 7,074,812, “Development of Muscle Mass in a Mammal“) nutraceutical using either natural or synthetic nicotine in a patented method for substantially accelerating the development of muscle mass and strength.
  • A proprietary formulated product for a sleep aide.
  • A proprietary formulated product for staying awake and alert.
  • A proprietary formulated product for strength and stamina.
  • A proprietary formulated product for enhancing libido while aiding erections.
Further information on the individual products, their previous registered and trademarked names, their new marketing plans, etc. will be issued as the company (SOMA Nutraceuticals, Inc.) and its management complete and implement these plans.